Challenges and Opportunities in Gene Delivery - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 76

[76] Kircheis R, Blessing T, Brunner S, Wightman L, Wagner E. Tumor targeting with surface-
shielded ligand-polycation DNA complexes. J Control Release 2001;72:165-70.
[77] Wiethoff CM, Smith JG, Koe GS, Middaugh CR. The potential role of proteoglycans in
cationic lipid-mediated gene delivery—studies of the interaction of cationic lipid-DNA
complexes with model glycosaminoglycans. J Biol Chem 2001;276:32806-13.
[78] Oupicky D, Konak C, Dash PR, Seymour LW, Ulbrich K. Effect of albumin and polyan-
ion on the structure of DNA complexes with polycation-containing hydrophilic nonionic
block. Bioconjugate Chem 1999;10:764-72.
[79] Martina M, Nicolas V, Wilhelm C, Ménager C, Barratt G, Lesieur S. The in vitro kinetics
of the interactions between PEGylated magnetic fluids loaded liposomes and macro-
phages. Biomaterials 2007;28:4143-53.
[80] Lubec G, Kuhn K, Latzka U, Reale E. Glomerular permeability for proteins of high
molecular weight entrapped in liposomes. Renal Physiol 1981;4:131-6.
[81] Latta H, Fligiel S. Mesangial fenestrations, sieving, filtration, and flow. Lab Invest
1985;52:591-8.
[82] Toshihide H, Satoshi I, Kimiko M, Hiroshi T, Masanori O. Mathematical description of
drug movement into tumor with EPR effect and estimation of its configuration for DDS.
Colloids Surf B 2010;75:42-6.
[83] Wu J, Zern M. Modification of liposomes for liver targeting. J Hepatol 1996;24:757-63.
[84] Huang R, Qu Y, Ke W, Zhu J, Pei Y, Jiang C. Efficient gene delivery targeted to the brain
using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer.
FASEB J 2007;21:1117-25.
[85] Upadhyay K, Agrawal H, Upadhyay C, Schatz C, Meins J, Misra A, et al. Role of
block copolymer nanoconstructs in cancer therapy. Crit Rev Ther Drug Carrier Syst
2009;26:157-205.
[86] Herceptin tastuzumab. http:// www.herceptin.com/index.jsp . [accessed on 05.01.10].
[87] Zhou Q, You Y, Wu C, Huang Y, Oupicky D. Cyclic RGD-targeting of reversibly stabi-
lized DNA nanoparticles enhances cell uptake and transfection in vitro . J Drug Targeting
2009;17:364-73.
[88] Garde S, Forte A, Ge M, Lepekhin E, Panchal C, Rabbani SA, et al. Binding and internal-
ization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing
cells and its antitumor effects. Anticancer Drugs 2007;18:1189-200.
[89] Han J, Oh Y, Kim D, Kim C. Enhanced hepatocyte uptake and liver targeting of metho-
trexate using galactosylated albumin as a carrier. Int J Pharm 1999;188:39-47.
[90] Banerjee R, Tyagi P, Li S, Huang L. Anisamide-targeted stealth liposomes: a potent car-
rier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 2004;112:
693-700.
[91] Mukherjee A, Prasad T, Rao N, Banerjee R. Haloperidol-associated stealth liposomes.
J Biol Chem 2005;280:15619-27.
[92] Auzenne E, Ghosh S, Khodadadian M, Rivera B, Farquhar D, Price R, et al. Hyaluronic
acid-paclitaxel: Antitumor efficacy against CD44 () human ovarian carcinoma xeno-
grafts. Neoplasia 2007;9:479-86.
[93] Bernfield M, Gotte M, Park P, Reizes O, Fitzgerald M, Lincecum J, et al. Functions of
cell surface heparin sulfate proteoglycans. Annu Rev Biochem 1999;68:729-77.
[94] Yanagishita M, Hascall V. Cell surface heparin-sulfate-proteoglycans. J Biol Chem
1992;267:9451-4.
[95] Patel M, Yanagishita M, Roderiquez G, Bou-Habib D, Oravecz T, Hascall V, et al. Cell-
surface heparin sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res
Hum Retroviruses 1993;9:167-74.